S-1/A: BioCardia Eyes $5.3 Million Capital Raise Through Common Stock and Warrant Offering

BioCardia, Inc. announces a best efforts offering to raise up to $5.3 million through the sale of common stock, pre-funded warrants, and common warrants to fund working capital and general corporate purposes.

Summary

• BioCardia, Inc. is undertaking a best efforts offering to sell up to 2,439,024 shares of common stock, along with an equal number of common warrants.
• Pre-funded warrants are also being offered to purchasers who would exceed beneficial ownership limits, with each pre-funded warrant accompanied by a common warrant.
• The assumed combined public offering price is $2.46 per share of common stock and accompanying common warrant.
• The common warrants have an assumed exercise price of $2.71 per share and expire five years from the issuance date.
• The company estimates net proceeds of approximately $5.3 million from the offering, after deducting placement agent fees and offering expenses.
• The funds are intended for working capital and general corporate purposes, including advancing biotherapeutic candidates and the biotherapeutic delivery partnering business.
• Certain members of the Board of Directors and non-director executive officers have indicated preliminary interest in purchasing a portion of the offering.
• The offering will terminate no later than September 27, 2024.
• A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the capital raise is necessary for the company's operations, it also involves dilution for existing shareholders and carries inherent risks associated with best efforts offerings.

Positives

• The offering provides BioCardia with additional capital to advance its biotherapeutic candidates and partnering business.
• The inclusion of warrants may make the offering more attractive to investors.
• The best efforts basis allows flexibility in the amount of capital raised.
• The company has the ability to use pre-funded warrants to accommodate investors with ownership limitations.

Negatives

• The offering is on a best efforts basis, so there is no guarantee that the company will raise the full $5.3 million.
• The offering will cause dilution to existing shareholders.
• There is no established trading market for the warrants.
• The assumed offering price may not be indicative of the final offering price.

Risks

• The company may not sell all of the securities offered.
• Investors will experience immediate dilution in the book value per share.
• The market price of the common stock may be volatile.
• The company's management will have broad discretion as to the use of proceeds from this offering.
• There is no guarantee that the company will regain compliance with or continue to satisfy the Nasdaq continued listing requirements.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and general corporate purposes, which include, but are not limited to, advancing our investigational biotherapeutic candidates and our biotherapeutic delivery partnering business.

Industry Context

This announcement reflects a common strategy for clinical-stage biotech companies to raise capital to fund ongoing research and development activities. The use of common stock and warrants is a typical structure to attract investors, balancing immediate capital with potential future gains.

Comparison to Industry Standards

• Comparable companies in the biotech sector, such as Athersys and Mesoblast, have also utilized public offerings of common stock and warrants to raise capital.
• The terms of this offering, including the warrant exercise price and expiration date, appear to be within the typical range for similar offerings in the biotech industry.
• The placement agent fee of 7.0% is also consistent with industry standards for best efforts offerings.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company will have additional capital to fund its operations and advance its pipeline.
• The offering may impact the company's ability to meet Nasdaq continued listing requirements.

Next Steps

• The company will proceed with the best efforts offering through A.G.P./Alliance Global Partners.
• The company will seek to list the shares and warrant shares on the Nasdaq Capital Market.
• The company will use the net proceeds for working capital and general corporate purposes.

Key Dates

Keywords

common stock, warrants, pre-funded warrants, offering, BioCardia, capital raise, placement agent, securities, BCDA